Ovid Therapeutics (OVID) Capital Expenditures Growth (3y) (2019 - 2024)
Ovid Therapeutics (OVID) Capital Expenditures Growth (3y) (2019 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 16.27% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -29.28% |
| Jun 30, 2024 | 103.47% |
| Dec 31, 2023 | -26.75% |
| Sep 30, 2023 | -31.05% |
| Jun 30, 2023 | -37.39% |
| Mar 31, 2023 | -28.64% |
| Dec 31, 2022 | 31.95% |
| Sep 30, 2022 | 178.49% |
| Jun 30, 2022 | 775.88% |
| Mar 31, 2022 | 91.21% |
| Dec 31, 2021 | 213.51% |
| Sep 30, 2021 | 27.62% |
| Jun 30, 2021 | -58.92% |
| Dec 31, 2020 | 183.66% |
| Sep 30, 2020 | 26.20% |
| Jun 30, 2020 | 52.50% |
| Mar 31, 2020 | -1.60% |
| Dec 31, 2019 | -14.88% |
| Sep 30, 2019 | -26.32% |
| Jun 30, 2019 | 49.82% |